Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-04-02
2010-10-12
Yu, Misook (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S350000, C422S067000, C435S006120
Reexamination Certificate
active
07812143
ABSTRACT:
The present invention provides identification of a thirty-five gene set that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway, methods of qualifying cancer status in a subject, methods of identifying an anti-tumor response in a subject, methods of monitoring the efficacy of a therapeutic drug in a subject, and methods of identifying an agent useful in the treatment of a cancer based on expression of the thirty-five gene set.
REFERENCES:
Davies, et al. “Mutations of the BRAF gene in human cancer” Nature. 2002. vol. 417, pp. 949-954.
Solit et al., “BRAF mutation predicts sensitivity to MEK inhibition” Nature. 2006. vol. 439, pp. 358-362.
Tsavachidou et al., “SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-TypeBRAFbut Not with the V599E Mutant” Cancer Research. 2004, vol. 64, pp. 5556-5559.
Bloethner et al., “Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines” Carcinogenesis. 2005. vol. 26, pp. 1224-1232.
Pratilas Christine
Rosen Neal
Edwards Angell Palmer & & Dodge LLP
Hunter-Ensor, Esq. Melissa
Lauro, Esq. Peter C.
Memorial Sloan-Kettering Cancer Center
Yu Misook
LandOfFree
Biomarkers for cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4222552